论著

儿童结缔组织病相关间质性肺病临床特点及治疗转归分析

  • 龚玲 ,
  • 舒畅 ,
  • 冉海波
展开
  • 重庆医科大学附属儿童医院呼吸科 国家儿童健康与疾病临床医学研究中心 儿童发育疾病研究教育部重点实验室 儿科学重庆市重点实验室(重庆 400014)

收稿日期: 2023-04-04

  网络出版日期: 2024-06-07

基金资助

重庆市科卫联合面上项目(2019 MSXM 009)

Clinical characteristics and treatment outcomes of connective tissue disease-associated interstitial lung disease in children

  • Ling GONG ,
  • Chang SHU ,
  • Haibo RAN
Expand
  • Department of Respiration Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorder, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

Received date: 2023-04-04

  Online published: 2024-06-07

摘要

目的 分析儿童结缔组织病相关间质性肺病(CTD-ILD)临床资料,提高对儿童CTD-ILD的认识。方法 回顾性分析2012年1月至2021年12月53例CTD-ILD住院患儿临床资料,包括临床表现、胸部HRCT、肺功能、治疗及转归等。结果 53例CTD-ILD患儿中,23例诊断CTD的同时经HRCT评估诊断为ILD,4例以ILD起病,26例CTD诊断ILD的时间跨度为15天~7年余。呼吸系统常见的症状为咳嗽(47.2%)、气促(28.3%)和啰音(26.4%),但有21例患儿无呼吸道症状,依据HRCT诊断ILD。胸部HRCT显示斑片影(64.2%)、条絮/条片影(55.6%)、条索影(37.7%)、网格/蜂窝影(24.5%)、囊状低密度影(24.5%)、磨玻璃影(22.6%)等。肺功能异常以弥散功能下降(46.5%)、限制性通气功能障碍(39.5%)和小气道功能障碍(32.6%)为主。经糖皮质激素、免疫抑制剂、生物制剂治疗后,48例患儿临床症状有好转。胸部HRCT:20例有好转,21例无明显变化,6例进展;肺功能:17例有好转,11例无明显变化,3例进展,8例正常。结论 儿童CTD-ILD临床症状缺乏特异性,胸部HRCT及肺功能检查有助于早期发现肺部病变,需积极完善检查并定期随访;治疗方案主要是糖皮质激素联合免疫抑制剂和/或生物制剂,但生物制剂在儿童中的应用需进一步研究。

本文引用格式

龚玲 , 舒畅 , 冉海波 . 儿童结缔组织病相关间质性肺病临床特点及治疗转归分析[J]. 临床儿科杂志, 2024 , 42(6) : 503 -508 . DOI: 10.12372/jcp.2024.23e0277

Abstract

Objective To analyze the clinical data of connective tissue disease-associated interstitial lung disease (CTD-ILD) in children, and to improve the understanding of CTD-ILD in children. Methods The clinical data of 53 hospitalized children with CTD-ILD from January 2012 to December 2021 were retrospectively analyzed, including clinical manifestations, chest HRCT, pulmonary function, treatment and outcome, etc. Results Among the 53 children with CTD-ILD, 23 children were diagnosed as ILD by HRCT at the same time of CTD diagnosis, 4 children had ILD onset, and 26 children were diagnosed as ILD with a time span of 15 days to more than 7 years. The common symptoms of respiratory system were cough (47.2%), shortness of breath (28.3%) and rales (26.4%). But there were 21 cases without respiratory symptoms, and ILD was diagnosed according to HRCT. Chest HRCT showed patchy shadows (64.2%), striped shadows (55.6%), streak shadows (37.7%), grid/honeycomb shadows (24.5%), cystic low-density shadows (24.5%) and ground glass shadows (22.6%), etc. The main pulmonary function abnormalities were diffusion dysfunction (46.5%), restrictive ventilation dysfunction (39.5%) and small airway dysfunction (32.6%). After treatment with glucocorticoids, immunosuppressants and biological agents, 48 children showed improvement in clinical symptoms. Chest HRCT showed improvement in 20 children, no significant change in 21 children, and progress in 6 children. Pulmonary function examination showed improvement in 17 children, no significant change in 11 children, progress in 3 children, and normal in 8 children. Conclusions The clinical symptoms of CTD-ILD in children are lack of specificity, and chest HRCT and pulmonary function tests are helpful for early detection of pulmonary lesions, so relevant examinations should be actively completed and regular follow-up should be conducted. Treatment options are glucocorticoids combined with immunosuppressants and/or biological agents, but the use of biological agents in children needs further study.

参考文献

[1] Gao Y, Moua T. Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review[J]. Mayo Clin Proc, 2020, 95(3): 554-573.
[2] 黄华, 金燕樑, 丁飞, 等. 儿童结缔组织性疾病相关间质性肺病的诊治进展[J]. 国际儿科学杂志, 2020, 47(11): 768-772.
[3] 唐晓蕾, 李彩凤, 赵顺英. 儿童结缔组织病相关肺损害[J]. 中国循证儿科杂志, 2016, 11(2): 148-156.
[4] Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management[J]. Respir Res, 2018, 19(1): 32.
[5] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9): 1725.
[6] Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392.
[7] Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347.
[8] Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides[J]. Clin Exp Nephrol, 2013, 17(5): 603-606.
[9] Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis[J]. Arthritis Rheum, 2007, 57(2): 203-212.
[10] 徐雪峰, 蒋敏, 刘秀云, 等. 儿童免疫相关性疾病临床实用热点问题专家建议系列之二——中国儿童结缔组织疾病相关间质性肺病变诊治专家建议[J]. 中国实用儿科杂志, 2020, 35(3): 174-179.
[11] Jeganathan N, Sathananthan M. Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment[J]. Lung, 2020, 198(5):735-759.
[12] 王妍华, 蒲丹, 罗静, 等. 147例常见结缔组织病相关间质性肺病的临床特征及转归分析[J]. 西安交通大学学报(医学版), 2019, 40(4): 598-603.
[13] 谢荣华, 吴振彪, 贾俊峰, 等. 305例结缔组织病相关间质性肺病临床特点分析[J]. 临床肺科杂志, 2016, 21(12): 2135-2138.
[14] Aurangabadkar GM, Aurangabadkar MY, Choudhary SS, et al. Pulmonary manifestations in rheumatological diseases[J]. Cureus, 2022, 14(9): e29628.
[15] Doshi JA, Mundhra KS, Shah DS,et al, Role of high-resolution CT thorax in diagnosing interstitial lung disease and its association with smoking and connective tissue disorder[J]. Cureus, 2022, 14(11): e31107.
[16] Huang H, Hu Y, Wu Y, et al. Lung involvement in children with newly diagnosed rheumatic diseases: characteristics and associations[J]. Pediatr Rheumatol Online J, 2022, 20(1): 71.
[17] Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases[J]. Mayo Clin Proc, 2019, 94(2): 309-325.
[18] Palmucci S, Galioto F, Fazio G, et al. Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay[J]. Insights Imaging, 2022, 13(1): 108.
[19] Hackner K, Stadler A, Schragel F, et al. Transbronchial lung cryobiopsy: prospective safety evaluation and 90-day mortality after a standardized examination protocol[J]. Ther Adv Respir Dis, 2022, 16: 17534666221077562.
[20] Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Clin Respir J, 2018, 12(3): 1084-1092.
[21] Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease[J]. Expert Rev Clin Immunol, 2016, 12(5): 509-520.
[22] 黄莎, 李凡. 结缔组织病相关间质性肺病诊断及治疗的研究进展[J]. 国际呼吸杂志, 2020, 40(15): 1160-1167.
[23] Nishi K, Ogura M, Tamai N, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review[J]. Pediatr Rheumatol Online J, 2022, 20(1): 60.
[24] Maruyama Y, Shigemura T, Kobayashi N, et al. Efficacy of tocilizumab for interstitial lung disease associated with polyarticular juvenile idiopathic arthritis[J]. Pediatr Int, 2022, 64(1): e14737.
[25] Maniscalco V, Marrani E, Rossi E, et al. Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease[J]. Scand J Rheumatol, 2021, 50(6): 491-492.
文章导航

/